Certified Advisory Corp’s Novo Nordisk NVO Stock Holding History

Certified Advisory Corp’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,000	Closed	-$26K	–	823
2019 Q1	$26K	Hold	1,000	–	–	0.01%	404
2018 Q4	$23K	Hold	1,000	–	–	0.01%	400
2018 Q3	$24K	Hold	1,000	–	–	0.01%	415
2018 Q2	$23K	Hold	1,000	–	–	0.01%	407
2018 Q1	$24K	Hold	1,000	–	–	0.01%	372
2017 Q4	$26K	Buy	+1,000	New	+$25.4K	0.02%	326

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Certified Advisory Corp's NVO Position: Q2 2019 in Review

Certified Advisory Corp sold out of Novo Nordisk (NVO) in Q2 2019, closing a stake of 1,000 shares — an estimated $26K sold.

Certified Advisory Corp first reported a position in NVO in Q4 2017 and held it in 6 quarters. The position peaked at $26K in Q1 2019. 559 funds tracked by Wall St. Rank hold NVO as of Q2 2019.

Certified Advisory Corp reported no remaining Novo Nordisk position as of Q2 2019 after selling out during the quarter.
Certified Advisory Corp sold 1,000 Novo Nordisk shares in Q2 2019, an estimated $26K.
Certified Advisory Corp first reported a position in Novo Nordisk in Q4 2017 and held it in 6 quarters.
Certified Advisory Corp's Novo Nordisk position peaked at $26K in Q1 2019.
559 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2019.

Based on Certified Advisory Corp's 13F filing for Q2 2019, filed 7 Aug 2019.